Disturbance of activity and attention. Disturbance of activity and attention
Conditions
Interventions
Placebo
Tablet Bupropion(150-300 mg/day) as intervention group for 6 weeks
Placebo for 6 weeks as control group
Intervention 1: Tablet Bupropion(150-300 mg/day) as intervention group for 6 weeks. Intervention 2: Placebo for 6 weeks as control group.
Treatment - Drugs
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: Diagnosis of ADHD based on DSM-IV ; age between 20-60 Exclusion Criteria:Chronic medical disease including seizure,cardiovascular disease, CVA and organic brain disease;substance abuse or dependence during past six months;nursing or pregnant patients; history of tic disorder; receiving of any psychotropics drugs during past two weeks, mental retardation ; history of suicide attempt, psychosis or aggressiveness; receiving psychotropic drugs; receiving psycho-stimulants or atomoxetine during past three months; bipolar disorder
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of ADHD. Timepoint: Week 0 (before treatment) and Weeks 3 and 6 after treatment. Method of measurement: by Adult ADHD Self-Report Scale and Conners Adult ADHD Rating Scales–Self-Report-screening version. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactProf. Shahin Akhondzadeh
Tehran University of Medical Sciences
Outcome results
None listed